Filing Details

Accession Number:
0001599901-24-000110
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-20 18:48:40
Reporting Period:
2024-06-17
Accepted Time:
2024-06-20 18:48:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1599901 Avidity Biosciences Inc. RNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1383731 F Michael Maclean C/O Avidity Biosciences, Inc.
10578 Science Center Drive, Suite 125
San Diego CA 92121
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-06-17 25,000 $0.00 69,093 No 4 A Direct
Common Stock Disposition 2024-06-18 11,228 $39.13 57,865 No 4 S Direct
Common Stock Acquisiton 2024-06-17 25,000 $0.00 82,865 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 A Direct
Footnotes
  1. Represents performance-based restricted stock units (PSUs). Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on September 11, 2023, and are eligible to vest upon the achievement of two company performance objectives. The PSUs reflected in this row represent the portion of the award that vested as a result of the achievement of the first performance objective (the Issuer's initiation of the Phase 3 HARBOR trial for del-desiran) (the Performance Condition).
  2. Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of those PSUs that vested on June 17, 2024 as a result of achievement of the Performance Condition. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.
  3. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.13. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. As a result of the achievement of the Performance Condition, on June 17, 2024, an additional 25,000 PSUs were earned by the Reporting Person on such date. On such date, such PSUs converted to time-based restricted stock units that will vest on December 17, 2024 subject to the Reporting Person's continued employment or service through such date.